Psychopharmacology Institute
2025-26 Psychopharmacology Updates

Advanced Psychiatric Prescribing for NPs

115 Contact Hours to meet your pharmacology requirements

View Memberships

Why NPs Choose Our Program

115 Contact Hours

1 CME = 1 contact hour, fully AANP-approved

Clinical Pearls

Real-world prescribing pearls you can use immediately

75+ Pharmacology Hours

Comprehensive pharmacology content for advanced prescribing competency

Choose Your Learning Style

Advance your nursing practice with the right learning format

Video, Audio, and Text

  • Video presentations
  • Audios in your podcast app
  • Text summaries with key points

Multiple Products

  • Video lectures
  • Expert interviews
  • Quick Takes: research updates

Practical Education

  • Practical clinical tips and pearls
  • Led by experts with real-world experience
  • Free of commercial bias

Peek Inside Our Library

No publications found
No publications found

Quick Take Vol. 76

Can lumateperone effectively treat depression with mixed features? Can GLP-1 agonists manage antipsychotic-induced weight gain? Is quetiapine superior to lithium for treatment-resistant depression? Do antidepressants accelerate cognitive decline in dementia patients? How do probiotics and prebiotics affect depression, anxiety, and cognition?

0.75 CMEs

Quick Take Vol. 75

What are the main considerations when choosing an antipsychotic for first-episode psychosis? How do side effects of antidepressants change over time? Do combinations of psychiatric medications increase Torsades risk? Is there sufficient evidence for psychedelics in treating substance use disorders? Can tea compounds benefit mood and sleep disorders through neurotransmitter modulation?

0.75 CMEs

Quick Take Vol. 74

What are the main reasons disulfiram is underutilized for alcohol use disorder? How do different antipsychotics compare regarding QT prolongation risks? What is the optimal dosage of lurasidone for bipolar depression ? How does clozapine's effectiveness compare to other antipsychotics? Which non-benzodiazepine medication options show the best balance of efficacy and side effects for insomnia in psychiatric patients?

0.75 CMEs

Quick Take Vol. 73

How do LAI antipsychotics impact mortality rates compared to oral medications in schizophrenia ? What dosages of medications are most effective for preventing bipolar disorder relapse and maintaining safety? Is olanzapine more effective than risperidone for managing BPS? Can lisdexamfetamine effectively treat methamphetamine use disorder? Does chronopharmacology impact psychiatric treatment efficacy and side effects?

0.75 CMEs

Quick Take Vol. 72

Can GLP-1 receptor agonists effectively treat alcohol use disorder? Which antidepressants cause the most weight gain? Do antidepressants increase fall risk in older adults? How effective and safe is ketamine for bipolar depression? Is aripiprazole truly a lower metabolic risk antipsychotic compared to olanzapine?

0.5 CMEs

Quick Take Vol. 71

What are the major risks of antipsychotic pneumonia and which medications increase this risk? How effective is metformin combined with lifestyle changes for managing antipsychotic-induced weight gain? What are the optimal lithium levels for maintenance treatment and acute mania? How does exercise potentially help improve depression symptoms through biological mechanisms? What role do B-complex vitamins play in cognitive function among depressed patients?

0.75 CMEs

Quick Take Vol. 70

How does clozapine affect OCD behaviors in schizophrenia patients? What is the relationship between valproate dosage and weight gain? Which dopamine agonist works best for treatment-resistant depression? Does delirium increase dementia risk in elderly patients? What treatment approaches show the strongest evidence for stimulant use disorder?

0.5 CMEs

Quick Take Vol. 69

How dangerous are clozapine-induced ileus and pneumonia compared to agranulocytosis? How does topiramate compare to naltrexone for alcohol use disorder? Should cariprazine be continued as maintenance therapy in bipolar disorder? How reliably can we diagnose Wernicke's encephalopathy? What role does gut bacteria play in major depression?

0.5 CMEs

Quick Take Vol. 68

What are the main benefits of long-acting injectables for women with schizophrenia? How might vitamin D impact dementia risk? What effect does lithium have on bone mineral density? How common is alcohol withdrawal syndrome? What are the long-term outcomes for patients with psychotic disorders?

0.5 CMEs

Quick Take Vol. 67

How common are antidepressant discontinuation symptoms and which medications are associated with higher rates? Can Akkermansia muciniphila help manage olanzapine-induced weight gain? How does climate change impact mental health outcomes? What is the current evidence for antidrug vaccines in treating substance use disorders? Are there cognitive deficits associated with COVID-19 infection and how significant are they?

0.5 CMEs

Quick Take Vol. 66

Can donanemab slow Alzheimer's progression? Does clozapine's agranulocytosis risk persist beyond the initial treatment period? Can antipsychotics cause both catatonia and neuroleptic malignant syndrome? What is the suicide risk in Parkinson's disease patients? Can AI predict antidepressant response and remission in major depression?

0.75 CMEs

Quick Take Vol. 65

Can SSRIs be safely combined with oral anticoagulants? Do long-term benzodiazepine users typically escalate doses over time? Are antidepressants effective for cognitive symptoms in late-life depression? How should psychosis, agitation and depression be managed in dementia patients? Which antidepressants perform best for efficacy, tolerability and outcomes in geriatric depression?

0.75 CMEs

Quick Take Vol. 64

Commentaries on papers covering hypochondriasis mortality risk, antipsychotic withdrawal syndrome, stimulant use in pregnancy, the gut-brain connection in schizophrenia, and sedative use and fall risk in the elderly.

0.75 CMEs

Quick Take Vol. 63

In this volume, we explore promising developments in psychiatric treatments, including a new drug (KarXT) for schizophrenia and an antipsychotic (iloperidone) for bipolar mania. This volume also investigates the use of machine learning to predict psychosis conversion, the differentiation between substance-induced psychosis and schizophrenia, and ways to reduce racial bias in physical restraint use in emergency rooms. Do we have an unconscious bias when making decisions about using restraints?

0.75 CMEs

Quick Take Vol. 62

In this Quick Take volume, we discuss a recent trial that showed a doubled risk of relapse in patients with schizophrenia when antipsychotic medication was reduced. We also touch on the use of psilocybin for treatment-resistant depression, which sounds promising—still, the need for concurrent psychotherapy and the potential long-term safety risks must be considered. Additionally, we talk about using famotidine for COVID-19–induced brain fog, real-world evidence supporting long-acting injectable antipsychotics for bipolar disorder, and effective management of poststroke depression.

0.5 CMEs

Quick Take Vol. 61

In this Quick Take volume, we revisit the utilization of droperidol as a strategy for handling agitation and ponder on the discontinuation of benzodiazepines and Z-drugs among hospitalized elderly patients. Are there alternate approaches for discontinuation that could be undertaken during hospitalization? We also question the efficacy of gabapentin in treating post-COVID-19 anosmia, its possible association with neurodegenerative diseases, and whether high-dose olanzapine is a feasible treatment for resistant schizophrenia. Finally, do antidepressants influence the effectiveness of psychotherapy?

0.5 CMEs

Quick Take Vol. 60

In this Quick Take volume, our faculty discuss the effectiveness of adjunctive cariprazine in the treatment of major depressive disorder with inadequate response to antidepressants and low-dose risperidone for delirium in elderly orthopedic patients. Our experts also examine the efficacy of memantine for trichotillomania and skin-picking disorder and investigate the link between psychiatric disorders and increased risk for cardiovascular disease. Finally, the real-world effectiveness of pharmacologic treatments for bipolar disorder is discussed.

0.5 CMEs

Quick Take Vol. 59

In this Quick Take volume, our expert faculty investigate the link between insomnia symptoms and stroke risk, analyze the long-term effectiveness of antipsychotics in treating schizophrenia, and examine the safety of oral antipsychotics for older adults after surgery. Our experts also assess the benefits and risks of medical cannabis in Parkinson's disease treatment and explore neuroradiological abnormalities in first-episode psychosis.

0.5 CMEs

Quick Take Vol. 58

In this Quick Take volume, our expert faculty examine a range of critical topics, beginning with an exploration of plasma concentrations of SSRI/SNRI post-bariatric surgery and their impact on depressive symptoms. They also investigate the potential of psychedelics as transformative therapeutics in mental health care as well as the efficacy and safety of antidepressants in patients suffering from both depression and other medical diseases. Additionally, the use of daridorexant among patients with chronic insomnia and an international research agenda focusing on clozapine-resistant schizophrenia are discussed.

0.5 CMEs

Quick Take Vol. 57

In this Quick Take volume, our expert faculty examine timely research on electroconvulsive therapy as an effective adjunct for clozapine in the treatment of ultra–treatment-resistant schizophrenia, trazodone as a possible first-line treatment for insomnia, and Silexan’s potential benefits for alleviating neuropsychiatric symptoms associated with post-COVID syndrome. Our faculty also discuss studies on medication risks, such as antipsychotic drugs and the risk for acute pancreatitis as well as benzodiazepines and the risk for suicide attempt.

0.5 CMEs

Quick Take Vol. 56

In this Quick Take volume, our expert faculty examine research on the possible effects of prenatal exposure to antidepressants across various trimesters of gestation as well as the safety and efficacy of lithium augmentation for the management of treatment-resistant depression. Our faculty also discuss studies regarding antipsychotics and liver safety as well as inappropriate medication use among older adults.

0.75 CMEs

Quick Take Vol. 55

In this Quick Take volume, our expert faculty examine research on tobacco use and nicotine dependence among adults with psychosis, the risk of irreversible sexual dysfunction associated with SSRIs, and the effects of dual orexin receptor antagonists on delirium prevention. Our faculty also discuss sleep disorders in Parkinson’s disease and the pharmacologic treatment of obsessive-compulsive disorder.

0.75 CMEs

Quick Take Vol. 54

In this Quick Take volume, our expert faculty examine research on the association between NSAIDs and reduced rates of delirium, antidepressants and apathy, and victimization and violence among patients with schizophrenia. Our women’s health expert also discusses the efficacy and safety of zuranolone on patients with postpartum depression as well as the risks of major malformations in infants after maternal exposure to benzodiazepines.

0.75 CMEs

Quick Take Vol. 53

In this Quick Take volume, our expert faculty examine research on the effects of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression; aripiprazole co-prescription on prolactin levels among hospitalized patients; and the use of colony-stimulating factor on the outcomes of patients undergoing clozapine rechallenge. Selected faculty experts also discuss the phenomenon of tardive syndromes and appropriate management for these as well as the effect of pharmacogenomic testing on the outcomes of major depressive disorder.

0.5 CMEs

Listen to All Our Website Content On An Audio Feed

Download all episodes on your favorite podcasting app, and earn CMEs.

Here's how:

  1. Download episodes from your audio feed.
  2. Earn CMEs by logging into our website.

Access 4 times more content than with our open podcast.

Audio feed preview showing a car dashboard and phone

What Other NPs Are Saying

The content is straight to the point and easy to understand.

As someone who prefers reading, I appreciate how well-organized the content is for skimming.

The lack of commercial bias in this program gives me peace of mind.

Get Instant Access Now

Pick a membership, cancel any time.

Bronze Membership

$297 (USD) /year
  • Up to 47 CMEs
  • 12 new CMEs per year
  • Unlimited downloads
  • Video Lectures
    Treatment updates, as bite-sized videos.
  • Expert Consultations
    Clinical pearls from interviews with experts
  • Quick Takes
    Research summaries in adult psychiatry
  • Brain Guides
    Practical guides for decision-making in psychopharmacology.
  • Audio Feed
    Audio versions of our content for on-the-go learning
BEST VALUE

Silver Membership

$347 (USD) /year
  • Up to 115 CMEs
  • 30 new CMEs per year
  • Unlimited downloads
  • Video Lectures
    Treatment updates, as bite-sized videos.
  • Expert Consultations
    Clinical pearls from interviews with experts
  • Quick Takes
    Research summaries in adult psychiatry
  • Brain Guides
    Practical guides for decision-making in psychopharmacology.
  • Audio Feed
    Audio versions of our content for on-the-go learning
30 Day Satisfaction Guarantee

If you are not completely satisfied with your membership, you can contact us
within 30 days and we will issue a full refund. No questions asked.